Be sure to check our sister interview main ratings news website

Motif Bio PLC “Peers are valued at significant premium in the US”

Northland Capital partners view: Today’s announcement brings Motif a step closer to US capital markets, where peers are valued at a significant premium to Motif. We believe that a NASDAQ listing would better align the company’s valuation to its closest peer, namely NASDAQ-listed Paratek (market capitalisation: $291m).

Motif appoints US advisor and auditor
n  Motif announced the appointment of U.S. healthcare investment bank MTS Health Partners (MTS) to advise on its future financing options within the U.S. market.

n  A NASDAQ listing continues to be an option for Motif in order to be aligned with several peer companies.

n  The Company has also appointed as its auditor PricewaterhouseCoopers LLP (PwC), one of the top four multinational professional services firms in the world.

n  Considerable progress has also been made with plans to identify strategic partners who are interested in licensing its Phase III asset, iclaprim, outside the U.S.
Year end Dec Revs ($m) Adj. EBITDA ($m) Adj. PBT ($m) Tax (%) Adj. EPS (c) PER (x) Div (c) Net cash ($m) Yield (%)
2012A – (0.7) (1.1) – (13.3) – – (6.6) –
2013A – (0.7) (1.1) – (13.2) – – (6.8) –
2014A – (1.1) (1.2) – (10.0) – – (6.8) –
2015E – (2.0) (2.9) – (4.7) – – 31.3 –

Source: Northland Capital Partners Limited. * Northland acts as Broker to Motif.

 
 
Read in Full
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Motif Bio Plc

    More articles like this

    Motif Bio Plc

    Motif Bio plc Proposed Placing to raise approximately £19.4m

    2nd June 2017

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of a conditional placing with new and

    Motif Bio Plc

    Motif Bio PLC Reports Year-End 2016 Financial Results

    2nd May 2017

    Motif Bio PLC (LON:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. Motif Bio made significant progress in 2016 towards our goal of

    Motif Bio Plc

    Motif Bio plc Update post NASDAQ IPO

    20th January 2017

    Motif Bio plc (LON:MTFB, NASDAQ:MTFB), is a late clinical stage antibiotic development company. The company completed its IPO on NASDAQ in November last year raising $25m before expenses. With the funds from the IPO the company

    Motif Bio Plc

    Motif Bio plc appoint ex NASDAQ listed Tyme Technologies CFO

    18th January 2017

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that Robert Dickey IV has been appointed as Chief Financial Officer. Mr. Dickey is an accomplished financial professional

    Motif Bio Plc

    Motif Bio PLC Update on US Public Offering

    31st October 2016

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, further to its announcement of 9 August 2016, said today that it is continuing to work towards pricing of its proposed public

    Motif Bio Plc

    Motif Bio plc 2 posters at ID Week in New Orleans

    15th September 2016

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that it will be presenting two poster studies at IDWeek, October 26 to 30 in New Orleans, USA.

    Motif Bio Plc

    Motif Bio plc progressing trials efficiently with latest update

    8th September 2016

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has given DirectorsTalk an update to REVIVE-1, one of Motif Bio’s two Phase 3 clinical trials currently enrolling patients with Acute

    © 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.